Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.

ABSTRACT: Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System (NHS) over the period between 2009 and 2019. Drug acquisition costs considering commercial discounts at public procurement procedures (hospital tenders) and uptake data for both originator and biosimilar as actual units consumed by the NHS were the two variables considered. Two scenarios were compared: a scenario where no biosimilars are available and the biosimilar scenario where biosimilars are effectively marketed. All molecules exposed to biosimilar competition during this period were included in the analysis. The robustness of the model w

SUBMITTER: Garcia-Goni M 

PROVIDER: S-EPMC8069914 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature